Abstract: Premature ejaculation is the most common form of sexual dysfunction among men. The pathophysiology of premature ejaculation appears to be multifactorial, implicating the need for multimodal therapeutic regimens to successfully treat premature ejaculation. Multiple treatment regimens have been shown to be effective in extending the time between penetration and ejaculation. These treatment modalities include everything from behavioral modifications and medications to diet alterations and major surgery. The goal of the present article was to review the commonly used treatment regimens used in the treatment of premature ejaculation, as well as to introduce and discuss the newest treatment routines under study for the treatment of premature ejaculation.
Introduction
The studies on the prevalence of PE place this pathology as the most common sexual dysfunction among men. 1 Various studies have found that between 20% and 30% of men experience PE; however, this condition is commonly underreported because of embarrassment of both the patient and the physician, as well as lack of awareness. 1 At first glance, the diagnosis of PE would seem straightforward; however, the diagnostic criteria have been hotly debated. 2, 3 There are several competing ideas about the correct way to diagnose PE. A psychological approach, which was initially used in DSM-IV, diagnoses the pathology based on subjective feelings rather than utilizing specific cut-off points for ejaculation time. 2, 3 Using this definition, PE was defined as ejaculation with both minimal stimulation and before the patient desires. This use of vague language had the potential to overdiagnose men who do not suffer from PE, and to underdiagnose men who do. 2, 3 Recently, this was changed in the DSM-V to include a cut-off time of ejaculation within 1 min of vaginal penetration that causes significant distress. 3 In contrast to the psychological theory, a definition created by Waldinger et al. proposed that PE should be defined solely based on the time between beginning intercourse and ejaculation, known as the IELT. 2 The World Health Organization's ICD-10 definition of PE includes both an inability to control ejaculation, as well as a cut-off of ejaculation within 15 s of beginning intercourse. 3 This debate over the definition of PE makes the assessment and diagnosis difficult for providers, further obscuring the prevalence of the pathology and delaying treatment. [1] [2] [3] For this reason, it is difficult to determine a true estimate of the prevalence of PE in the population. Many patients suffering from PE experience increased distress, anxiety and depression, as well as overall dissatisfaction with sexual intercourse. 1, 3 Clarifying the diagnostic criteria for PE might allow undiagnosed patients to receive treatment that could improve their quality of life. of 75-90%. 4 However, even with the best therapies, this measurement does not reflect a cure rate; rather, it shows an improvement in IELT that could be as low as a single second. This fact leaves the all-important question: is there a true solution to PE? If so, what is it?
Current therapies Behavioral techniques
Two of the most common behavioral therapies used in the treatment of PE are the "start-stop" technique and the "squeeze" technique. Developed by Semans in 1956, the "start-stop" technique involves stimulating the penis until one feels the urge to ejaculate, then removing the stimulation until the urge to ejaculate subsides. 5 By repeating this maneuver multiple times before allowing oneself to ejaculate, the "start-stop" technique allows the patient to improve control over the ejaculatory response by learning to identify the physical and emotional parameters involved in arousal. 6 Although once considered the gold standard for the treatment of PE, the "start-stop" technique has been under scrutiny, as recent studies disagree on the effectiveness of this behavioralbased treatment. [7] [8] [9] The "squeeze" technique, established by Masters and Johnson in 1970, involves squeezing the glans of the penis until the urge to ejaculate subsides. 10 Similar to the "start-stop" technique, the "squeeze" technique was originally reported to have a 97.8% success rate; however, this has not been replicated in more recent studies.
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SSRIs
Although the pathophysiology of PE is relatively unknown, one hypothesis behind the etiology of PE is the dysfunction of 5-HT receptors. 12 Elevated concentrations of 5-HT are present at many receptors that have been found to be involved with ejaculatory control, and activation of the central 5-HTmediated system has an overall inhibitory effect on ejaculation. 13 Specifically, activation of 5-HT1B and 5-HT2C receptors has been shown to have inhibitory effects on the ejaculation pathway, delaying ejaculation, whereas activation of 5-HT1A receptors has been found to precipitate ejaculation. 13 The role of the 5-HT1A in mediating ejaculation is shown by the fact that fluvoxamine, an SSRI that has a high specificity for the 5-HT1A receptor, does not show a significant increase in IELT. 13, 14 Furthermore, Waldinger et al. proposed that the pathophysiology of PE could possibly be a result of hypofunction of the 5-HT2C receptor and/or hyperfunction of the 5-HT1A receptor. 14, 15 This hypofunction of the 5-HT2C receptor, as well as low levels of 5-HT transmission in general, is thought to be associated with a low threshold for sexual arousal and ejaculation. SSRIs can activate 5-HT2C receptors and raise this threshold, subsequently increasing the IELT. 15 It is believed that SSRIs induce delayed ejaculation by inhibiting presynaptic and somatodendritic serotonin transporters, thereby increasing total central 5-HT neurotransmission and activation of postsynaptic 5-HT receptors. 16 An alternate theory is that by increasing the amount of serotonin in the synaptic cleft, SSRIs desensitize 5-HT1A and 5-HT1B receptors, causing an overall inhibitory effect on the ejaculation pathway. 16 The effect of SSRIs on PE has been seen as early as a few days after starting the medication; however, most patients notice a significant increase in ejaculatory time 1-2 weeks after beginning the medication, strengthening the thought that SSRIs treat PE through receptor desensitization. 17 Furthermore, because 5-HT receptor desensitization can cause the body to upregulate the production of 5-HT receptors, the efficacy of SSRIs might decrease after 6-12 months of consistent use. 17 SSRIs used in the off-label treatment of PE include fluoxetine, paroxetine, citolapram, fluvoxamine and sertraline. 12 Currently, no SSRIs are approved by the FDA for the treatment of PE. One SSRI, dapoxetine hydrochloride, has been approved for the treatment of PE in some European and Asian countries. 18 Adverse effects, such as reduced libido, mild headache, nausea, sweating and dizziness, have been associated with the use of SSRIs. 19 
SNRIs
SNRIs are a class of drugs commonly used in the treatment of psychiatric disorders and chronic pain syndromes. 20, 21 SNRIs, by increasing serotonin and norepinephrine in the synaptic cleft, might have a role in the management of PE given the hypothesis that the pathophysiology of PE could stem from the abnormal neuromodulation of central and peripheral serotonin receptors. 13 Athanasios et al. showed that duloxetine, when compared with a placebo, increases IELT in patients suffering from PE. 22 Furthermore, duloxetine was shown to increase sexual desire and partner satisfaction when used in patients with PE. 22 Because personal distress and perceived control over ejaculation are thought to play a vital role in the pathophysiology of PE, duloxetine might also help patients with PE through regulation of mood and emotions. [23] [24] [25] One study carried out by Ozcan et al. showed that duloxetine improved IELT, as well as personal distress related to control over ejaculation, in men with PE. 26 
TCAs
Because primary PE is thought to be a result of dysfunctional 5-HT receptors, TCAs are another class of drugs that have been studied in the treatment of this condition. The first published study showing the effectiveness of TCAs in the treatment of PE was carried out by Eaton in 1973 . In that study, Eaton reported that there was "an almost 100% positive reaction" when using clomipramine in the treatment of PE. 27 Like SSRIs and SNRIs, TCAs exert their effects by acting as serotonin and norepinephrine transport inhibitors, increasing the amount of serotonin and norepinephrine in the synaptic cleft, and delaying ejaculation through activity at 5-HT receptors. 15, 28 There have been multiple studies showing that TCAs, particularly clomipramine daily, have a positive effect on sexual satisfaction when used to treat PE. [29] [30] [31] In fact, one study showed that daily clomipramine had a greater effect on IELT than fluoxetine or sertraline. 32 Compared with other TCAs, clomipramine has been shown to have a particularly strong affinity for serotonin transporters, possibly explaining why it has a stronger effect on PE than other TCAs. 28 The effect of clomipramine might also be enhanced by its ability to inhibit contraction of the vas deferens, which plays a role in ejaculation. 13 One drawback of using TCAs is the side-effect profile, which includes, fatigue, nausea, dry mouth, hypotension, flushing and dizziness. 32 
Local anesthetics
One of the physiological factors believed to play a role in the pathophysiology of PE is a hypersensitive response to penile stimulation. 33 The ejaculatory response consists of an afferent neuronal input, which is carried through the pudendal nerves and is triggered by penile stimulation, and an efferent neuronal output carried by the sympathetic nerves of the T10-T12 paraspinal sympathetic ganglia to the male reproductive organs to trigger ejaculation. 34 Multiple studies have shown that men with PE have a lower penile vibratory threshold, higher bulbocavernosus-evoked potentials and larger dorsal nerve somatosensory evoked potential amplitudes. 33, [35] [36] [37] These findings suggest that by masking the sensory input from the glans through local anesthetics applied directly to the penis, men who suffer with PE could increase their IELT. 38 Local anesthetics are membrane-stabilizing drugs that inhibit voltage-gated sodium channels, thereby decreasing synaptic transmission and neuronal hypersensitivity, thus increasing the threshold for ejaculation. 39 Topical anesthetics used in the treatment of PE include topical lidocaine, benzocaine, prilocaine and SS Cream. One of the most studied local anesthetic mixtures used in the treatment of PE is the mixture of lidocaine and prilocaine. Lidocaine and prilocaine are two solids that when mixed together form a liquid mixture without the use of a solvent. 40 This cream, which contains 2.5% of both lidocaine and prilocaine and has been named EMLA or eutectic mixture of local anesthetic, has been shown in multiple studies to increase patients' IELT and satisfaction of sexual performance if applied to the penis before intercourse. [41] [42] [43] Tempe, another anesthetic mixture of lidocaine and prilocaine, is one of the newest products being developed for the treatment of PE. Unlike most mixtures of lidocaine and prilocaine, which are creams, Tempe is an aerosol formulation that is dissolved in a non-chlorofluorocarbon propellant, which is unique in the fact that it does not penetrate fully keratinized skin. 44 This allows Tempe to concentrate its desensitizing effect on the glans penis, decreasing the potential for unwanted side-effects. 45 The newest local anesthetic used in the treatment of PE is Promescent. Promescent is a lidocaine-only topical spray that can be applied to the penis before intercourse to desensitize the glans and therefore theoretically increase IELT. 46 Currently, no clinical trials have reported a statistically significant increase in IELT with the use of Promescent. Promescent is unique in the fact that it does not contain prilocaine, which when applied topically can cause the unusual side-effect of methemoglobinemia. 47 Promescent, unlike Tempe, was allowed by the FDA for treatment of PE, and is available prescription-free in North America. 48 
Tramadol
Tramadol is a potent centrally acting opioid-based analgesic used in the treatment of acute and chronic pain. 49 Tramadol exerts its analgesic effects by binding to centrally located mu opioid pain receptors, and by inhibiting the reuptake of both serotonin and norepinephrine. 50 Interestingly, tramadol has also been shown to act as a 5-HT2C receptor antagonist. 51 It is thought that tramadol's effectiveness in the treatment of PE is due to the neuromodulation of serotonin and norepinephrine receptors. 51, 52 Tramadol has shown promising results in multiple studies examining its use in the medical management of patients with PE. [53] [54] [55] [56] [57] [58] Khan et al. showed a significant increase in IELT in patients that were treated with tramadol. 53 A comprehensive meta-analysis carried out by Wu et al. showed an increase in IELT of 3 min when comparing tramadol with a placebo. 54 Unlike other treatments for PE, tramadol does have a potential for both abuse and dependence; however, these episodes are rare, especially in patients that use tramadol intermittently. 55 
Alpha-blockers
The prostate and the seminal vesicles play a vital role in the physiology of ejaculation, and the smooth muscle of both of these organs contains alpha-1 receptors. 59, 60 Considered the gold standard for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia, alpha-1 blockers have been reported to cause ejaculatory dysfunction. 61 Although this ejaculatory dysfunction was originally thought to be caused by retrograde ejaculation, recent studies have shown that it is caused by contraction failure of the seminal vesicles, resulting in emission reduction. 61, 62 Given these data, researchers began studying the effects of alpha-1 blockers on the treatment of PE. Multiple studies have shown the effectiveness of alpha-1 blockers in minimizing PE. 63, 64 The most common alpha-1 blockers used in the treatment of PE include tamsulosin, silodosin, terazosin and alfuzosin, with all showing a statistically significant increase in IELT. 65 At therapeutic doses, side-effects of alpha-blockers are rare, but include anorgasmia, dry mouth, nasal congestion, drowsiness and orthostatic hypotension. 66 
Phosphodiesterase inhibitors
PDE5 inhibitors are drugs that have been approved by the FDA for the treatment of ED. 67 Recently, multiple studies have shown that PDE5 inhibitors might also play a role in the treatment of PE. [68] [69] [70] [71] The exact mechanism behind the effectiveness of PDE5 inhibitors in the medical management of patients with PE is currently unknown. In a systematic review on the efficacy of PDE5 inhibitors in the treatment of PE, McMahon et al. hypothesized that PDE5 inhibitors might exert their effects through multiple mechanisms including reduced performance anxiety, increased nitric oxide release, reduced sympathetic tone, and dilatation of the smooth muscle of the vas deferens and seminal vesicles, which could possibly delay ejaculation. 70, 72 Frequently prescribed off-label as a treatment for PE, sildenafil, a commonly used PDE5, has been shown to be helpful in the treatment of PE. 73 However, studies are conflicting on the effectiveness of sildenafil monotherapy on IELT, with some studies failing to show any significant increase in IELT, whereas others show an increase in IELT. 74, 75 Furthermore, sildenafil has been shown to be more effective in increasing IELT and sexual satisfaction when supplemented with paroxetine. 76 One drawback in the use of sildenafil and paroxetine as a duo therapy for PE is in increase in adverse side-effects. 76 In patients that suffer from both ED and PE, PDE5 inhibitors should be considered as a first-line treatment in the medical management of PE. 75 
Experimental treatments Dorsal nerve modulation
Modulation of the DPN currently shows promising potential as a treatment for PE. [77] [78] [79] [80] [81] Patients with PE have been found to have an increased number of branches of their DPN. 82, 83 This increased frequency could be a potential cause of the increased sensitivity found in patients with PE. With knowledge of this underlying pathophysiology, the two resulting treatment options are modulation of the nerves or permanent ablation. Two trials involving DPN resection increased the IELT compared with placebo. 80, 81 Interestingly, the authors were able to include a placebo arm to the trial by using circumcision as the control procedure. 80 Of the previous trials involving dorsal nerve ablation, the longest follow up was <2 years. 80, 81 Although there has been no trial comparing modulation with ablation, radiofrequency modulation seems the more viable option moving forward. Dorsal nerve modulation has a theoretical decreased permanency and risk of ED. 79 Neuromodulation has already been proven safe and effective in dealing with urinary and fecal incontinence. 84 So far, the evidence for treatment based on neuromodulation is weak, as only case series have been carried out. 79 Prospective cohorts or RCTs are necessary to verify the validity of the previous reports. Also, increasing the length of time for follow up after the treatment is important to identify ongoing rates of ED after the procedure. Additionally, biothesiometry testing of the penis in patients with PE before and after dorsal nerve neuromodulation are also future directions of research.
Acupuncture
The efficacy of acupuncture in treating PE has been tested in several RCTs. [85] [86] [87] A systematic review found that just three RCTs have shown acupuncture to be more effective than a placebo (sham acupuncture) in treating PE or ED. 85 Acupuncture has not been shown to be as effective when compared with paroxetine; however, acupuncture with electrical stimulation in conjunction with paroxetine was more effective than paroxetine alone. 86, 88 Standard acupuncture or its electrical counterpart is likely not a truly effective individual treatment for PE. However, with polypharmacy becoming more of a problem in finding treatments for patients with multiple comorbidities, having non-pharmacological options that have shown efficacy can be extremely beneficial. In future studies, the particular steps of acupuncture and the location of needle placement need to be more clearly demonstrated. 85 It could be that these treatments involved different patterns of neural stimulation due to lack of standardization, leaving the acupuncture treatments in each of these trials dissimilar. Additionally, further testing of acupuncture as an adjunctive therapy is likely to be of benefit.
Yoga
Yoga has been proposed as a potential treatment for PE. It has shown efficacy in significantly prolonging the IELT in prospective studies. 89 However, some trials have shown no improvement of PE with yoga in comparison with a placebo. 90 The difference in outcomes could be attributed to longer length of treatment in the statistically significant trials. 89, 90 Also, the type of yoga was not readily distinguished between the trials. The underlying mechanism of yoga treatment is unknown. The potential mechanism could lie in strengthening or decreasing the tension of the pelvic musculature, but none of the studies included any physical parameters in their data. 89, 90 Any improvement in IELT could instead be as a result of the emphasis in yoga for bodily awareness that could potentially increase the patient's awareness of impending ejaculation, allowing more effective withdrawal and pause methods. Future trials need to more readily include the specific variables of the type of yoga being carried out.
Future developments Medical or sexual device
The utilization of medical devices to allow an increase in IELT is a future possibility for the treatment of PE. Surprisingly, although many devices are in the marketplace, none have been put to scientifically rigorous studies. Unfortunately, the only study involving a vibration device utilized it in addition to psychological or behavioral therapy. 9 Furthermore, the devices used in these studies were not designed for men with PE. Future devices could potentially increase the threshold to which men with PE respond to sexual stimuli.
Botulinum toxin
Botulinum toxin has been thoroughly utilized in different aspects of medicine. It is used in dermatology for smoothing skin; it is used in gastrointestinal for decreasing the hypertonia of dysfunctional sphincters. In urology, it is approved for treatment of hyperactive bladder or detrusor over activity. 91 Botulinum toxin has been proposed as a potential treatment for PE. 92 The mechanism would likely rely on the toxin's ability to paralyze the neural end-plate, decreasing the ability of the muscles associated with ejaculation to contract. 92 In an RCT using rat models, injections of botulinum toxin into each bulbospongiosus muscle increased the IELT relative to the group with saline injections. 93 Interestingly, there was no effect on the rats' ability to achieve and maintain an erection. 93 In transitioning to human studies, it will be increasingly important to measure the effect that the treatment has on ED and libido.
Circumcision
Circumcision has been proposed as a permanent treatment for PE caused by hypersensitivity of the glans. In a recent prospective cohort, patients post-circumcision at 1-year follow up had significantly higher IELT, sexual satisfaction and subjective control over ejaculation when compared with uncircumcised controls. 94 However, multiple systematic reviews published 2 years prior found that the rate of PE or other sexual dysfunctions were not significantly different between circumcised and uncircumcised men in the general population. 95, 96 Another systematic review correlating the histological and anatomical differences caused by circumcision found that the prepuce does not serve a sexual function, and circumcision likely has no effect on sexual functioning. 97 The differences between the first study's findings could be due to a number of factors. First, circumcision is a surgical procedure, and there was no sham procedure included to account for its placebo effect. 94 Second, there could be a fundamentally different neural or physiological response to circumcision carried out as an adult in comparison with childhood. 98 The relationship between PE and circumcision is further muddled, because circumcision after the age of 7 years has been found to be a risk factor for PE. 99 A large prospective cohort would help to address these issues by following children to adulthood and determining long-term risks of childhood circumcision for PE. Also, future trials utilizing circumcision as a treatment arm need to include a sham procedure to better act as the placebo arm of the trial.
Caffeine
Caffeine is a recently proposed pharmacological treatment for PE. A recent double-blind RCT found that using 100 mg of caffeine 2 h before the onset of intercourse significantly increased the IELT of patients with PE. 100 The paper only included 40 patients, and the placebo portion of the trial was not well described. 100 However, with the use of caffeine so ubiquitous in modern society, the ease of treating PE with over-the-counter caffeine tablets is clearly appealing. There is a strong social stigma associated with PE. Practitioners might find that utilizing a treatment that has very little underlying stigma might help the psychological impact of the patient's disease process. Future studies are clearly necessary to elucidate the relationship between caffeine and PE. Such studies will require much larger treatment groups and a more aptly described placebo arm of the trial. Additionally, it would be helpful to know the optimal time variable between caffeine consumption and intercourse. Finally, it could be helpful to attempt to use consumption of coffee instead of just caffeine pills.
Penile frenulum lengthening
Lengthening of the penile frenulum has been tested as a potential treatment for PE. Only one study was found in our search. A case series involving 34 men with PE and a shortened penile frenulum found that surgically increasing the penile frenulum length led to a significant increase in IELT and subjective sexual satisfaction. 101 That study had a significant proportion of patients with underlying ED that showed improvement of these symptoms after treatment. 101 Because of the high comorbidity of ED in this population, the results of that study are likely due to the improvement of ED leading to a concomitant improvement in PE. 102 Future cross-sectional research would be helpful in understanding the rate of PE in patients with a shortened penile frenulum; however, research in the general population is unlikely to be beneficial, as there are no data suggesting an improvement in erectile function in patients with an already normal penile frenulum length.
Varicocelectomy
Varicoceles are another anatomical abnormality that has been associated with PE. 103 Case series have shown that treatment of a patient's varicocele increased IELT in patients with and without PE. 103, 104 Interestingly, there might be an increase in erectile function and testicular testosterone production after treatment. 103 The mechanism of varicocelectomy for improvement PE has not been elucidated. It could be as a result of the increase in postoperative testosterone, improvement in ED, or a difference in blood flow or testicular pressure. Correlational studies to the incidence of PE in patients with underlying varicoceles would be helpful to understand this relationship. However, this treatment will continue to only be a possible treatment for patients with concomitant PE and varicocele.
DA-8031
Although SSRIs are already a common treatment for PE, and dapoxetine has emerged as an on-demand treatment of PE, a new compound, DA-8031, has shown excellent efficacy in animal models and could be a viable PE treatment in the future. [105] [106] [107] Like the other SSRIs, it works specifically on the serotonin receptor, increasing the amount of extracellular serotonin in the dorsal raphe nucleus. 106 The molecule works by inhibiting the muscular contractions of the bulbospongiosus muscle, and decreasing seminal vesicle pressure during both electrical and chemical stimulation of ejaculation in rat models. 107 DA-8031 also increased the IELT in rats without affecting the mating attempts or the refractory period between ejaculations. 108 Although its pharmacological parameters have not yet been tested in humans, based on animal models this medication would likely be used as an on-demand treatment for PE. Much like dapoxetine in humans, the compound has a short half-life when consumed orally by rat models. 108 DA-8031 has a half-life of approximately 1.8 h in rats, compared with dapoxetine's average of 18 h in humans. 18 This could allow for increased dosages with potentially fewer sideeffects as a result of the rapid removal of the drug from the body. Future research in human studies needs to readily appreciate the efficacy of DA-8031 in comparison with current SSRIs. Additionally, it will be important to identify DA-8031's pharmacological parameters, and determine if it can be dosed with an improved side-effect profile as a result of its shortened half-life.
Pelvic floor rehabilitation
Pelvic floor rehabilitation in treatment of PE involves steps to understand and control the contraction of the pelvic muscles in regard to sexual arousal, sexual stimulus, and ejaculation. 109, 110 These treatments involve initial sessions in which patients are taught about the role that pelvic muscles play in ejaculation, followed by later sessions in which patients learn how to control those muscles throughout sexual intercourse. 109 It has shown benefit in increasing the IELT in case series. 111 However, this process was only tested on a shortterm basis after treatment, and at 6 months, the effects had already begun to decrease. 111 Pelvic floor rehabilitation was also not as effective as SSRIs when compared in a randomized study. However, the authors failed to include a placebo arm to the trial, so the total effect of pelvic floor rehabilitation is undetermined. 112 Pelvic floor rehabilitation also improves the quality of erections and increases the intracavernosal pressure. 6 Some or all of the improvement in PE could be due to a concomitant improvement in ED. 6 A previous systematic review noted that behavioral therapies are significantly effective both individually and as a combination with drug therapy. 113 It will be important for future studies to readily identify the specific form of behavioral therapy being undertaken. Additionally, it would be helpful to compare pelvic floor rehabilitation with the traditional "stop-start" or "squeeze" techniques. Pelvic floor rehabilitation represents a fairly cheap therapy without the risk of pharmacological sideeffects. Its addition to any existing treatment for PE should be considered.
Resiniferatoxin
Resiniferatoxin is a naturally occurring plant-based resin, which is an incredibly potent version of capsaicin. 114 The compound has the ability to activate primary afferent sensory neurons by increasing calcium permeability. This influx is initially met with a significant burning sensation followed by analgesia as a result of neuronal death caused by calcium overload. 115, 116 Resiniferatoxin has been shown to improve IELT in patients with PE. 117 Strangely, resiniferatoxin was significantly more effective in patients with redundant prepuce, further complicating the relationship between circumcision and PE. 94, 95, 117 Unfortunately, in patients without redundant prepuce, the treatment was not more effective than a placebo, but the study population was particularly small. 117 Further study is necessary in nearly every aspect of resiniferatoxin's mechanism and potential utility. It will be important to compare the efficacy of resiniferatoxin with previously used anesthetics, and to thoroughly determine the long-term risk of PE as a result of potentially permanent damage to nerve endings.
Hyaluronic acid injections
Hyaluronic acid injection is an interesting subcategory of potential PE treatments. The injections are placed in the dermis, increasing the distance between nerve endings and the skin. 118 It serves the dual purpose of decreasing sensation while increasing the volume and girth of the penile head, theoretically increasing the sexual satisfaction of the patient's partner. 118, 119 After treatment, patients had an increased IELT as well as increased satisfaction from both partners. 119, 120 However, the constancy of the changes in the volume of the penis has not been fully determined. 118, 119 At 5-year follow up, the injection had decreased by an average of 15%. 121 Additionally, the authors claim that the injections do not affect erection quality; however, that determination is not based on standardized criteria. [119] [120] [121] Future studies of hyaluronic acid will need to utilize a saline or phosphodiesterase injection to allow a comparison and placebo arm with continued monitoring for exacerbation of erectile function.
Folic acid
Folic acid is water soluble and readily available over the counter. The vitamin's cheap cost and absence of negative side-effects makes it an ideal pharmacological treatment for PE. 122 Folic acid levels have been found to be negatively correlated with PE, with folic acid deficiency being considered a risk factor for decreased ejaculatory latency. 123 Because of the benefit of SSRIs in the treatment of PE, the mechanism proposed has been folic acid's effect on the serotonin pathway. 124 However, previous studies have shown a correlation between folic acid deficiency and ED. 125 Additionally, folic acid supplementation has been shown to improve erectile function when given concomitantly with a phosphodiesterase inhibitor. 126 Therefore, the association of folic acid and PE could be due to folic acid's beneficial effect on patients' erectile function. 126 Although folic acid appears to play more of a role in ED, the vitamin's cheap and benign nature necessitates thorough study in association with PE. Ongoing studies need to assess folic acid's ability to improve PE when used as monotherapy, as well as its potential augmentation of SSRI treatment.
Experimental animal models
Satureja montana
The plant, Satureja montana has been tested on rat models as a potential treatment for PE. 127 It is unclear how the hypothesis originated, as there are no previous studies or professional suggestion that the plant had sexual properties. In rat models, S. montana was able to increase the ejaculatory latency while also decreasing the refractory time. 127 The proposed mechanism included the plant's ability to increase levels of testosterone in male rats. 127 Although that study seems promising, future studies need to further illustrate the underlying mechanism of S. montana. Unfortunately, testosterone levels have not been found to be a negative predictor for PE in humans. 128, 129 In fact, studies have shown that patients with PE have been found to have higher testosterone levels than normal controls. 128, 130 Further study of S. montana in animal models is necessary to identify its ability to increase the ejaculatory latency. If its mechanism lies outside of its ability to increase testosterone, then it could still be a potential treatment for PE in the future.
Epelsiban
There is evidence that oxytocin receptors play an important role in the modulation of ejaculation. 131 In rat models, blockade of the oxytocin receptor has been shown to inhibit ejaculation without affecting the penile musculature or seminal vesicle pressure. 132 Epelsiban works as an oxytocin receptor antagonist. 133 However, in its only study when randomized and double-blinded, it did not perform significantly better than placebo. 134 Although epelsiban might not be effective in treatment of PE, this does not necessarily discredit this class of medication from being a potential treatment option in the future. 
Conclusions
Moving forward, urologists, psychiatrists and primary care doctors alike have to tailor their treatment of PE to the patient as an individual to improve outcomes. Each presentation of PE is unique in and of itself. As we increase our understanding of PE, a single cause has not been found; instead, we continue to discover underlying differences in patients with PE. A patient's pathology has the potential to have different amounts of anatomical, physiological and psychological components, and the understanding of how each of these processes works together is difficult to elucidate pathophysiologically. As medical professionals strive to discover new treatment options for PE, it will be imperative to continue developing multimodal therapeutic regimens using both current and emerging therapies in order to expand treatment strategies for resistant cases (Table 1) . One potential strategy is the development of a standardized treatment algorithm (Fig. 1 ). With such an algorithm, clinicians can initially utilize the most successful and cost effective treatment options, adding or exchanging additional treatments based on patient response and the suspected underlying disease process.
